Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg Registry.
Neuroblastoma
childhood cancer
proton beam therapy
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
30 10 2022
30 10 2022
Historique:
received:
21
09
2022
revised:
22
10
2022
accepted:
25
10
2022
entrez:
10
11
2022
pubmed:
11
11
2022
medline:
15
11
2022
Statut:
epublish
Résumé
Despite an intensive multimodal treatment approach, approximately 50% of high-risk (HR) neuroblastoma (NB) patients experience progression. Despite the advances in targeted therapy, high-dose chemotherapy, and other systemic treatment options, radiation therapy (RT) to sites of relapsed disease can be an option to reduce tumor burden and improve chance for disease control. Patients who received salvage irradiation with proton beam therapy (PBT) for local or metastatic relapse of HR NB within the prospective registry trials KiProReg and ProReg were eligible for this retrospective analysis. Data on patient characteristics, multimodality therapy, adverse events, and oncologic endpoints were evaluated. Adverse events were assessed before, during, and after PBT according to common terminology criteria for adverse events (CTCAE) V4.0. Between September 2013 and September 2020, twenty (11 male; 9 female) consecutive patients experiencing local ( Our study demonstrates the efficacy and safety of RT/PBT for recurrent HR NB in a multimodality second-line approach. To better define the role of RT for these patients, prospective studies would be desirable.
Sections du résumé
BACKGROUND
Despite an intensive multimodal treatment approach, approximately 50% of high-risk (HR) neuroblastoma (NB) patients experience progression. Despite the advances in targeted therapy, high-dose chemotherapy, and other systemic treatment options, radiation therapy (RT) to sites of relapsed disease can be an option to reduce tumor burden and improve chance for disease control.
METHODS
Patients who received salvage irradiation with proton beam therapy (PBT) for local or metastatic relapse of HR NB within the prospective registry trials KiProReg and ProReg were eligible for this retrospective analysis. Data on patient characteristics, multimodality therapy, adverse events, and oncologic endpoints were evaluated. Adverse events were assessed before, during, and after PBT according to common terminology criteria for adverse events (CTCAE) V4.0.
RESULTS
Between September 2013 and September 2020, twenty (11 male; 9 female) consecutive patients experiencing local (
CONCLUSION
Our study demonstrates the efficacy and safety of RT/PBT for recurrent HR NB in a multimodality second-line approach. To better define the role of RT for these patients, prospective studies would be desirable.
Identifiants
pubmed: 36354709
pii: curroncol29110649
doi: 10.3390/curroncol29110649
pmc: PMC9689739
doi:
Banques de données
DRKS
['DRKS00005363l']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8222-8234Références
J Pediatr Surg. 2011 Jan;46(1):97-102
pubmed: 21238648
Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):849-54
pubmed: 20207502
Pediatr Blood Cancer. 2018 Dec;65(12):e27408
pubmed: 30270551
Biol Blood Marrow Transplant. 2018 May;24(5):1005-1012
pubmed: 29307718
J Clin Oncol. 2006 Nov 20;24(33):5259-64
pubmed: 17114659
Eur J Med Chem. 2020 Dec 1;207:112818
pubmed: 32937281
J Clin Oncol. 2020 Jul 1;38(19):2160-2169
pubmed: 32343642
Eur J Cancer. 2020 Jan;124:47-55
pubmed: 31726247
Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):892-8
pubmed: 24462383
Pediatr Blood Cancer. 2018 Jan;65(1):
pubmed: 28748630
Eur J Cancer. 2019 Apr;111:50-58
pubmed: 30822684
Eur J Cancer. 2021 Feb;144:1-8
pubmed: 33316634
Radiother Oncol. 2008 Nov;89(2):141-9
pubmed: 18692928
Front Oncol. 2021 Jan 20;10:617506
pubmed: 33552991
Eur J Cancer. 2014 Jan;50(1):170-7
pubmed: 24021349
Cancer. 2003 Jul 1;98(1):155-65
pubmed: 12833468
Acta Oncol. 2013 Apr;52(3):580-8
pubmed: 22909391
Eur J Cancer. 2009 Nov;45(16):2835-42
pubmed: 19616426
Cancer. 1991 Nov 1;68(9):1999-2006
pubmed: 1913549
Nat Rev Clin Oncol. 2012 May 15;9(7):391-9
pubmed: 22585002
Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):1015-22
pubmed: 22138463
Cancer. 2017 Dec 15;123(24):4914-4923
pubmed: 28885700
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
In Vivo. 2018 Jan-Feb;32(1):159-164
pubmed: 29275314
Lancet Oncol. 2021 Dec;22(12):1764-1776
pubmed: 34780709
Children (Basel). 2019 Jan 17;6(1):
pubmed: 30658459